Tonolo G, McMillan M, Polonia J, Pazzola A, Montorsi P, Soro A, Glorioso N, Richards M A
Medical Research Council Blood Pressure and Renal Unit, Western Infirmary, Glasgow, United Kingdom.
Am J Physiol. 1988 Jun;254(6 Pt 2):F895-9. doi: 10.1152/ajprenal.1988.254.6.F895.
The effects and clearance of synthetic atrial natriuretic peptide (alpha-hANP) were investigated in eight patients with end-stage renal failure and six normal volunteers. ANP or vehicle was infused for 1 h at 10 pmol.kg-1.min-1 in random order on two separate occasions. During ANP infusions in end-stage renal patients, microhematocrit rose by 9.8 +/- 2% (P less than 0.005, n = 8), from base-line values of 0.24 +/- 0.02. Serum protein and albumin rose consistently. In contrast, during placebo infusions, no significant changes were seen. Blood pressure, heart rate, plasma renin concentration, serum creatinine, and electrolytes did not change significantly during either study phase. In end-stage renal failure patients, metabolic clearance rate of infused ANP was 1.04 +/- 0.095 l/min and its plasma half-life was 4 min 34 s. In normal volunteers, metabolic clearance rate was 2.6 l/min and its plasma half-life 3 min 30 s. The data suggest that ANP promotes contraction of plasma volume via a mechanism independent of renal function and also indicate that the kidney is not the only organ involved in the ANP metabolism.
对8例终末期肾衰竭患者和6名正常志愿者研究了合成心钠素（α-hANP）的作用及清除情况。在两个不同的时间段，以随机顺序按10 pmol·kg⁻¹·min⁻¹的剂量静脉输注心钠素或赋形剂1小时。在终末期肾病患者输注心钠素期间，微血细胞比容从基线值0.24±0.02上升了9.8±2%（P＜0.005，n = 8）。血清蛋白和白蛋白持续升高。相比之下，在输注安慰剂期间，未见明显变化。在两个研究阶段，血压、心率、血浆肾素浓度、血清肌酐和电解质均无显著变化。在终末期肾衰竭患者中，输注的心钠素代谢清除率为1.04±0.095升/分钟，血浆半衰期为4分34秒。在正常志愿者中，代谢清除率为2.6升/分钟，血浆半衰期为3分30秒。这些数据表明，心钠素通过一种独立于肾功能的机制促进血浆容量收缩，也表明肾脏并非参与心钠素代谢的唯一器官。
